Cyprotex PLC Trading Update (1741D)
October 23 2015 - 2:00AM
UK Regulatory
TIDMCRX
RNS Number : 1741D
Cyprotex PLC
23 October 2015
Cyprotex PLC
("Cyprotex" or the "Company" or the "Group")
Trading update
Cyprotex PLC (AIM: CRX), the preclinical ADME-Tox services
company, provides an update on revenue and profit guidance for the
year to 31 December 2015.
Trading update
The financial performance of the Company for the first nine
months of the year is ahead of expectations driven by continuing
strong growth in UK revenues and whilst there still remain
challenges as referred to in previous announcements, particularly
in the US operations which still need some attention but which are
much improved from earlier in the year, the Board expects that its
full year revenues and EBITDA will exceed current market
expectations.
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20
Cyprotex) 7496 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors:
Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1200 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME screening services, mechanistic toxicology and high
content toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling using PBPK, including Cloe(R) PK for in vivo
PK prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTBSBDGSUDBGUD
(END) Dow Jones Newswires
October 23, 2015 02:00 ET (06:00 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2024 to May 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From May 2023 to May 2024